Pressure Biosciences (PBIO) 0.2531 $PBIO
Pressure BioSciences Receives First Purchase Order for its Barozyme HT48 High-throughput System
PR Newswire - Tue Feb 10, 6:44AM CST
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
, a leader in the development and sale of broadly enabling sample preparation solutions using pressure cycling technology ("PCT" -based instruments and consumables to the worldwide life sciences industry, today announced the receipt of the first purchase order for its new Barozyme HT48 High-throughput System. The Company also announced the receipt of a request for a quotation for the possible purchase of a second Barozyme HT48 System; the request came from an existing European customer.
Pressure BioSciences, Inc. to Present at the SeeThruEquity Winter Microcap Investor Conference
PR Newswire - Thu Feb 05, 8:17AM CST
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company" today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview and business update at the SeeThruEquity ("STE" Winter Microcap Investor Conference this week in New York City. Mr. Schumacher's presentation at STE is scheduled for Thursday, February 5 at 11:00am at the Convene Times Square (810 Seventh Avenue).
Pressure BioSciences, Inc. Provides Update on Recent Equity Transactions
PR Newswire - Wed Jan 21, 8:31AM CST
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company" (http://www.pressurebiosciences.com), a leader in the design, development and sale of pressure-based instruments and consumables for the biological research market worldwide, today provided an update on two recent equity transactions totaling $1,166,000.
Pressure BioSciences, Inc. to Present at the 8th Annual OneMedForum Investor Conference - San Francisco
PR Newswire - Mon Jan 12, 7:31AM CST
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company" today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview at the 8th Annual OneMedForum Investor Conference in San Francisco, CA on Monday, January 12th at 12pm PST. The Investor Conference is being held at the San Francisco Marriott Marquis.
PharMerica Now a Strong Buy, Raised Guidance a Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 8:30AM CST
On Jan 2, 2015, Zacks Investment Research upgraded PharMerica Corp. (PMC) to a Zacks Rank #1 (Strong Buy)
PMC: 24.40 (-0.18), OCR: 76.89 (+0.14), AFAM: 30.88 (+0.37)
S&P Capital IQ Initiates Coverage on Pressure BioSciences, Inc. in S&P Capital IQ Factual Stock Reports
PR Newswire - Wed Dec 17, 9:35AM CST
S&P Capital IQ (MHFI) announced today that it has commenced Standard & Poor's Factual Stock Report coverage on Pressure BioSciences Inc. (OTCQB: PBIO).
MHFI: 102.19 (unch)
Pressure BioSciences Inc., (OTCQB: PBIO), Exclusive Interview for Interlinked's Investment News Channel at FSXinterlinked Investment Conference
PRWeb - Fri Dec 12, 6:02AM CST
Pressure BioSciences Inc., (OTCQB: PBIO), Exclusive Interview for Interlinked's Investment News Channel, InterlinkedTV at FSXinterlinked Investment Conference.
Pressure BioSciences Ships Third Barozyme HT48 System
PR Newswire - Wed Dec 10, 9:38AM CST
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company" today announced the commencement of the third independent evaluation of its new Barozyme HT48 high-throughput system. The evaluation will take place in the laboratory of Dr. William E. Funk of the Feinberg School of Medicine at Northwestern University. The Funk Laboratory focuses on developing and applying biomarker methods to explore environmental risk factors associated with chronic diseases, cancers, and other complex disorders. The Funk Laboratory is a current customer of the Company's patented pressure cycling technology ("PCT" instrument and consumable products.
Pressure BioSciences Ships First Two Barozyme HT48 Systems
PR Newswire - Tue Nov 18, 7:25AM CST
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company" today announced the installation of its first two Barozyme HT-48 high throughput systems for independent evaluation and subsequent potential sale. One system was placed in the laboratory of Dr. Radoslav Goldman of Georgetown University while the other was placed in the laboratory of a leading biotechnology company. In both settings, the Company believes the new systems will deliver important and unique capabilities for the analysis and characterization of biological samples. Both groups are current customers of the Company's patented pressure cycling technology ("PCT" -based products.
Pressure BioSciences, Inc. to Host Third Quarter 2014 Earnings Conference Call on Tuesday, November 18, 2014
ACCESSWIRE - Mon Nov 17, 3:05PM CST
SOUTH EASTON, MA / ACCESSWIRE / November 17, 2014 / Pressure BioSciences, Inc. (OTCQB
BIO) will host a conference call to discuss the results of the third quarter 2014, to be held Tuesday, November 18, 2014 at 4:30 PM Eastern Time.
Pressure BioSciences, Inc. Reports Third Quarter 2014 Financial Results and Provides Business Update
PR Newswire - Mon Nov 17, 8:42AM CST
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company" today announced financial results for the three and nine-month periods ended September 30, 2014, which included record products and services revenue compared to any prior nine-month period. The Company also provided a business update.
Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform
PR Newswire - Mon Oct 27, 6:50AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company" , a worldwide leader in the development and sale of high pressure-based sample preparation systems to the life sciences research market, today announced that Professor Ruedi Aebersold and his team presented a novel, accurate, highly reproducible, and robust method to allow - for the first time - routine high-throughput protein analysis on small needle biopsy samples by mass spectrometry (generally the method of choice for high-throughput protein analysis) within 12 hours. The method combines PBI's patented pressure cycling technology ("PCT" sample preparation platform with the novel SWATH mass spectrometry method developed by Dr. Aebersold's group in collaboration with AB SCIEX. Professor Aebersold and his team discussed their findings in several well-attended presentations at the 13th Human Proteome Organization World Congress, held October 5-8, in Madrid, Spain.
Week In Review: Roche Seeks China Partners With First-In-Class, Best-In-Class Products
ChinaBio Today - at Seeking Alpha - Sun Oct 26, 12:46PM CDT
Featured Companies In an exclusive interview, Dr. Darren Ji (Vice President and Global Head of Roche Partnering, Asia and Emerging Markets) told ChinaBio Today that Roche ( OTCQX:RHHBY ) ( OTCPK:RHHBF ) remains entirely focused on novel drugs for...
FMI: 48.88 (+0.17), AKER: 3.50 (+0.20), WX: 41.53 (+0.45)
Pressure BioSciences Announces Partnership with Powertech Technology Company Ltd. to Develop China Market for PBI's PCT Platform
PR Newswire - Mon Oct 20, 8:30AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company" today announced the continued expansion of its global sales outreach with a three-year, exclusive distribution agreement with Powertech Technology Company Ltd ("Powertech" , headquartered in Xiamen, China. Powertech is one of China's most recognized and prestigious distributors of analytical instruments and other equipment to the biotechnology, pharmaceutical, agricultural, environmental, food safety, and commercial testing laboratory markets. Powertech supports its customers with a network of 18 distribution offices, a maintenance center, an applications laboratory, and multiple sub-dealers. Powertech's current business partners include Dupont, GE Healthcare, Sartorius, Zeiss, and Agilent.
Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland
PR Newswire - Wed Oct 01, 7:15AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company" , a worldwide leader in the development and sale of high pressure-based sample preparation systems to the life sciences research market, today announced it has been invited to present at the 2nd Global Life Sciences Conference in Warsaw, Poland. The Conference will take place at the Warsaw Stock Exchange on October 2, 2014. Mr. Richard T. Schumacher, President and CEO of PBI, will present a business overview during the Company Sessions, between 8am -11am EDT.
Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems
PR Newswire - Fri Sep 19, 8:55AM CDT
Biotech companies make announcements illustrating significant progress in medical technology, development of emerging drug systems and advanced Laboratory Instrumentation. Companies in focus today are: (OTC: PBIO), Benton, Dickinson and Company (NYSE: BDX), Thermo Fisher Scientific Inc. (NYSE: TMO), Regado Biosciences Inc. (NASDAQ: RGDO), Sangamo Biosciences Inc. (NASDAQ: SGMO) and Hologic Inc. (NASDAQ: HOLX)
BDX: 143.71 (+0.72), TMO: 127.61 (+0.78), SGMO: 15.40 (+0.14), HOLX: 30.46 (+0.21), RGDO: 1.17 (+0.02)
Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System
PR Newswire - Fri Sep 19, 7:31AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company" today announced it has received and approved all parts required to build nine high throughput Barozyme HT48 instruments and has begun to manufacture the new PCT-based instrument system. The Company believes the first instrument will be ready for shipment by mid-October and that additional Barozyme instruments will be built and released at a rate of about one per week thereafter.
Steady Growth and Cutting-Edge Technologies Are Trademarks of Pressure BioSciences, Inc. (PBIO)
ACCESSWIRE - Mon Sep 15, 7:45AM CDT
Boca Raton, FL / ACCESSWIRE / September 15, 2014 / Thanks to a combination of market ingenuity and a strong scientific core, life science stalwart Pressure BioSciences (OTCQB BIO) continues to enjoy a resurgence of relevance as a veteran company. PBIO's patented "pressure cycling technology, "or PCT", is an up-and-coming, exciting, critically acclaimed resource for scientific sample preparation by its unique ability to offer unparalleled control of the actions of molecular cell and tissue samples through an intense pressure system. This process is used in applications as diverse as forensics, bio-marker discovery, and vaccine development.
Pressure BioSciences, Inc. to Present at Rodman & Renshaw and SeeThruEquity NY Investment Conferences
PR Newswire - Wed Sep 10, 9:56AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company" today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview and business update at the Rodman and Renshaw ("Rodman" and SeeThruEquity ("STE" Investment Conferences this week in New York City. Mr. Schumacher's presentation at Rodman is scheduled for Wednesday, September 10 at 12:05pm in the Palace Hotel. Mr. Schumacher's presentation at STE is scheduled for Thursday, September 11 at 9:00am at the Convene Times Square.
Pressure BioSciences Inc. ("PBI" (OTCQB: PBIO) Exclusive Interview for Interlinked's Investment News Channel, InterlinkedTV at FSXinterlinked Investment Conference
PRWeb - Thu Aug 28, 5:02AM CDT
Pressure BioSciences Inc., ("PBI" (OTCQB: PBIO) was one of the presenting companies at the recent FSXinterlinked Investment Conference held at the Four Seasons Hotel in Westlake Village, California.
Pressure BioSciences Receives First Purchase Order for its Barozyme HT48 High-throughput System
PR Newswire - Tue Feb 10, 6:44AM CST
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
, a leader in the development and sale of broadly enabling sample preparation solutions using pressure cycling technology ("PCT" -based instruments and consumables to the worldwide life sciences industry, today announced the receipt of the first purchase order for its new Barozyme HT48 High-throughput System. The Company also announced the receipt of a request for a quotation for the possible purchase of a second Barozyme HT48 System; the request came from an existing European customer. Pressure BioSciences, Inc. to Present at the SeeThruEquity Winter Microcap Investor Conference
PR Newswire - Thu Feb 05, 8:17AM CST
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview and business update at the SeeThruEquity ("STE" Winter Microcap Investor Conference this week in New York City. Mr. Schumacher's presentation at STE is scheduled for Thursday, February 5 at 11:00am at the Convene Times Square (810 Seventh Avenue). Pressure BioSciences, Inc. Provides Update on Recent Equity Transactions
PR Newswire - Wed Jan 21, 8:31AM CST
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
(http://www.pressurebiosciences.com), a leader in the design, development and sale of pressure-based instruments and consumables for the biological research market worldwide, today provided an update on two recent equity transactions totaling $1,166,000. Pressure BioSciences, Inc. to Present at the 8th Annual OneMedForum Investor Conference - San Francisco
PR Newswire - Mon Jan 12, 7:31AM CST
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview at the 8th Annual OneMedForum Investor Conference in San Francisco, CA on Monday, January 12th at 12pm PST. The Investor Conference is being held at the San Francisco Marriott Marquis. PharMerica Now a Strong Buy, Raised Guidance a Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 8:30AM CST
On Jan 2, 2015, Zacks Investment Research upgraded PharMerica Corp. (PMC) to a Zacks Rank #1 (Strong Buy)
PMC: 24.40 (-0.18), OCR: 76.89 (+0.14), AFAM: 30.88 (+0.37)
S&P Capital IQ Initiates Coverage on Pressure BioSciences, Inc. in S&P Capital IQ Factual Stock Reports
PR Newswire - Wed Dec 17, 9:35AM CST
S&P Capital IQ (MHFI) announced today that it has commenced Standard & Poor's Factual Stock Report coverage on Pressure BioSciences Inc. (OTCQB: PBIO).
MHFI: 102.19 (unch)
Pressure BioSciences Inc., (OTCQB: PBIO), Exclusive Interview for Interlinked's Investment News Channel at FSXinterlinked Investment Conference
PRWeb - Fri Dec 12, 6:02AM CST
Pressure BioSciences Inc., (OTCQB: PBIO), Exclusive Interview for Interlinked's Investment News Channel, InterlinkedTV at FSXinterlinked Investment Conference.
Pressure BioSciences Ships Third Barozyme HT48 System
PR Newswire - Wed Dec 10, 9:38AM CST
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
today announced the commencement of the third independent evaluation of its new Barozyme HT48 high-throughput system. The evaluation will take place in the laboratory of Dr. William E. Funk of the Feinberg School of Medicine at Northwestern University. The Funk Laboratory focuses on developing and applying biomarker methods to explore environmental risk factors associated with chronic diseases, cancers, and other complex disorders. The Funk Laboratory is a current customer of the Company's patented pressure cycling technology ("PCT" instrument and consumable products. Pressure BioSciences Ships First Two Barozyme HT48 Systems
PR Newswire - Tue Nov 18, 7:25AM CST
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
today announced the installation of its first two Barozyme HT-48 high throughput systems for independent evaluation and subsequent potential sale. One system was placed in the laboratory of Dr. Radoslav Goldman of Georgetown University while the other was placed in the laboratory of a leading biotechnology company. In both settings, the Company believes the new systems will deliver important and unique capabilities for the analysis and characterization of biological samples. Both groups are current customers of the Company's patented pressure cycling technology ("PCT" -based products. Pressure BioSciences, Inc. to Host Third Quarter 2014 Earnings Conference Call on Tuesday, November 18, 2014
ACCESSWIRE - Mon Nov 17, 3:05PM CST
SOUTH EASTON, MA / ACCESSWIRE / November 17, 2014 / Pressure BioSciences, Inc. (OTCQB
BIO) will host a conference call to discuss the results of the third quarter 2014, to be held Tuesday, November 18, 2014 at 4:30 PM Eastern Time. Pressure BioSciences, Inc. Reports Third Quarter 2014 Financial Results and Provides Business Update
PR Newswire - Mon Nov 17, 8:42AM CST
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
today announced financial results for the three and nine-month periods ended September 30, 2014, which included record products and services revenue compared to any prior nine-month period. The Company also provided a business update. Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform
PR Newswire - Mon Oct 27, 6:50AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
, a worldwide leader in the development and sale of high pressure-based sample preparation systems to the life sciences research market, today announced that Professor Ruedi Aebersold and his team presented a novel, accurate, highly reproducible, and robust method to allow - for the first time - routine high-throughput protein analysis on small needle biopsy samples by mass spectrometry (generally the method of choice for high-throughput protein analysis) within 12 hours. The method combines PBI's patented pressure cycling technology ("PCT" sample preparation platform with the novel SWATH mass spectrometry method developed by Dr. Aebersold's group in collaboration with AB SCIEX. Professor Aebersold and his team discussed their findings in several well-attended presentations at the 13th Human Proteome Organization World Congress, held October 5-8, in Madrid, Spain. Week In Review: Roche Seeks China Partners With First-In-Class, Best-In-Class Products
ChinaBio Today - at Seeking Alpha - Sun Oct 26, 12:46PM CDT
Featured Companies In an exclusive interview, Dr. Darren Ji (Vice President and Global Head of Roche Partnering, Asia and Emerging Markets) told ChinaBio Today that Roche ( OTCQX:RHHBY ) ( OTCPK:RHHBF ) remains entirely focused on novel drugs for...
FMI: 48.88 (+0.17), AKER: 3.50 (+0.20), WX: 41.53 (+0.45)
Pressure BioSciences Announces Partnership with Powertech Technology Company Ltd. to Develop China Market for PBI's PCT Platform
PR Newswire - Mon Oct 20, 8:30AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
today announced the continued expansion of its global sales outreach with a three-year, exclusive distribution agreement with Powertech Technology Company Ltd ("Powertech" , headquartered in Xiamen, China. Powertech is one of China's most recognized and prestigious distributors of analytical instruments and other equipment to the biotechnology, pharmaceutical, agricultural, environmental, food safety, and commercial testing laboratory markets. Powertech supports its customers with a network of 18 distribution offices, a maintenance center, an applications laboratory, and multiple sub-dealers. Powertech's current business partners include Dupont, GE Healthcare, Sartorius, Zeiss, and Agilent. Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland
PR Newswire - Wed Oct 01, 7:15AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
, a worldwide leader in the development and sale of high pressure-based sample preparation systems to the life sciences research market, today announced it has been invited to present at the 2nd Global Life Sciences Conference in Warsaw, Poland. The Conference will take place at the Warsaw Stock Exchange on October 2, 2014. Mr. Richard T. Schumacher, President and CEO of PBI, will present a business overview during the Company Sessions, between 8am -11am EDT. Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems
PR Newswire - Fri Sep 19, 8:55AM CDT
Biotech companies make announcements illustrating significant progress in medical technology, development of emerging drug systems and advanced Laboratory Instrumentation. Companies in focus today are: (OTC: PBIO), Benton, Dickinson and Company (NYSE: BDX), Thermo Fisher Scientific Inc. (NYSE: TMO), Regado Biosciences Inc. (NASDAQ: RGDO), Sangamo Biosciences Inc. (NASDAQ: SGMO) and Hologic Inc. (NASDAQ: HOLX)
BDX: 143.71 (+0.72), TMO: 127.61 (+0.78), SGMO: 15.40 (+0.14), HOLX: 30.46 (+0.21), RGDO: 1.17 (+0.02)
Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System
PR Newswire - Fri Sep 19, 7:31AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
today announced it has received and approved all parts required to build nine high throughput Barozyme HT48 instruments and has begun to manufacture the new PCT-based instrument system. The Company believes the first instrument will be ready for shipment by mid-October and that additional Barozyme instruments will be built and released at a rate of about one per week thereafter. Steady Growth and Cutting-Edge Technologies Are Trademarks of Pressure BioSciences, Inc. (PBIO)
ACCESSWIRE - Mon Sep 15, 7:45AM CDT
Boca Raton, FL / ACCESSWIRE / September 15, 2014 / Thanks to a combination of market ingenuity and a strong scientific core, life science stalwart Pressure BioSciences (OTCQB
BIO) continues to enjoy a resurgence of relevance as a veteran company. PBIO's patented "pressure cycling technology, "or PCT", is an up-and-coming, exciting, critically acclaimed resource for scientific sample preparation by its unique ability to offer unparalleled control of the actions of molecular cell and tissue samples through an intense pressure system. This process is used in applications as diverse as forensics, bio-marker discovery, and vaccine development. Pressure BioSciences, Inc. to Present at Rodman & Renshaw and SeeThruEquity NY Investment Conferences
PR Newswire - Wed Sep 10, 9:56AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview and business update at the Rodman and Renshaw ("Rodman" and SeeThruEquity ("STE" Investment Conferences this week in New York City. Mr. Schumacher's presentation at Rodman is scheduled for Wednesday, September 10 at 12:05pm in the Palace Hotel. Mr. Schumacher's presentation at STE is scheduled for Thursday, September 11 at 9:00am at the Convene Times Square. Pressure BioSciences Inc. ("PBI"
(OTCQB: PBIO) Exclusive Interview for Interlinked's Investment News Channel, InterlinkedTV at FSXinterlinked Investment Conference PRWeb - Thu Aug 28, 5:02AM CDT
Pressure BioSciences Inc., ("PBI"
(OTCQB: PBIO) was one of the presenting companies at the recent FSXinterlinked Investment Conference held at the Four Seasons Hotel in Westlake Village, California. 
